FOUNDATIONONE®CDx

PATIENT	TUMOR TYPE	REPORT DATE
Lin, Hung Chun	Brain glioblastoma (GBM)	28 Feb 2023
	COUNTRY CODE	ORDERED TEST #
	TW	ORD-1570860-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Brain glioblastoma (GBM)
NAME Lin, Hung Chun
DATE OF BIRTH 30 March 1956
SEX Male
MEDICAL RECORD # 44684868

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Brain
SPECIMEN ID S112-04410C (PF23017)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 07 February 2023
SPECIMEN RECEIVED 21 February 2023

Biomarker Findings

Microsatellite status - MS-Stable
Tumor Mutational Burden - 4 Muts/Mb

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

EGFR A289T
PTEN P213fs*8 - subclonal†
CTNNB1 splice site 1804-1G>A
TERT promoter -124C>T
TP53 K132E

2 Disease relevant genes with no reportable alterations: *IDH1, PDGFRA*

† See About the Test in appendix for details.

Report Highlights

- Variants with **diagnostic implications** that may indicate a specific cancer type: ***TERT* promoter -124C>T** (p. 7)
- Targeted therapies with potential clinical benefit **approved in another tumor type**: **Erlotinib** (p. 9), **Gefitinib** (p. 9), **Osimertinib** (p. 10)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 11)
- Variants with **prognostic implications** for this tumor type that may impact treatment decisions: ***TERT* promoter -124C>T** (p. 7)

PATHOLOGIST COMMENTS

Douglas A. Mata, MD, MPH 28-Feb-2023

This assay is not validated to identify chromosome-level cytogenetic aberrations. However, manual review of the copy-number profile reveals several whole chromosome/arm/segmental gains and losses including but not limited to gain of chromosome 7 and losses of chromosomes 10 and 13. Clinical correlation is advised.

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	**No therapies or clinical trials.** See Biomarker Findings section	
Tumor Mutational Burden - 4 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section	
GENOMIC FINDINGS	**THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)**	**THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)**
***EGFR* -** A289T	none	Erlotinib
		Gefitinib
8 Trials see p. 11		Osimertinib
***PTEN* -** P213fs*8 - subclonal	none	none
10 Trials see p. 13		

Electronically signed by Douglas A. Mata, MD, MPH | 28 February 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

BIOMARKER

Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS

Low-level MSI has been reported in 5-9% of glioblastoma (GBM) samples[6-8]. A large-scale study did not find high-level microsatellite instability (MSI-H) in any of 129 GBM samples[6], although a small-scale study reported MSI-H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs[9]. The frequency of MSI has been reported to be increased in relapsed compared to primary GBM[6], in GBMs with a previous lower grade astrocytoma[7], and in giant cell GBM compared to classic GBM[8].

FINDING SUMMARY

Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[10]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[10-12]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[13-15]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[10,12,14-15].

BIOMARKER

Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[16-18], anti-PD-1 therapies[16-19], and combination nivolumab and ipilimumab[20-25]. In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported[16,26-27]. However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti-PD-1[28-29] or anti-PD-L1[30] therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD-1 or PD-L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.

FREQUENCY & PROGNOSIS

Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)[31]. For pediatric patients, high TMB has been reported in a subset of high-grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB[32-33]. Increased TMB has been reported to correlate with higher tumor grade in glioma[34] and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD)[28], as well as with shorter OS of patients with diffuse glioma[35].

FINDING SUMMARY

Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[16,26-30].

GENE
EGFR

ALTERATION
A289T

TRANSCRIPT ID
NM_005228.3

CODING SEQUENCE EFFECT
865G>A

VARIANT CHROMOSOMAL POSITION
chr7:55221821

VARIANT ALLELE FREQUENCY (% VAF)
17.1%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

For patients with non-small cell lung cancer (NSCLC), EGFR activating mutations may predict sensitivity to EGFR-TKIs, including erlotinib[47], gefitinib[48-51], afatinib[52-55], dacomitinib[56], and osimertinib[53,57]; however, the data for patients with other tumor types are limited[58-63]. Patients with EGFR-mutated bithalamic glioma have reported responses to osimertinib[64-65]. In a case series of 11 patients with bithalamic gliomas with EGFR mutations, EGFR inhibitors, including osimertinib, showed improved survival; however, it showed a lack of significant clinical responses[61]. On the basis of preclinical data, EGFR mutations confer sensitivity to EGFR inhibitors, including osimertinib[61].

FREQUENCY & PROGNOSIS

EGFR alterations have been reported in 13.2% of anaplastic astrocytomas, 5.3-15.9% of glioblastoma multiformes (GBMs), and 0% of pilocytic astrocytomas in several genomic studies of CNS tumors[66-69]. In GBMs, Missense mutations in the EGFR extracellular domain have been found in 10-15% of cases and approximately half have a low-level amplification of the mutated allele[70-71]. In a study of IDH-wildtype GBM samples, EGFR alterations were detected in 50% (117/232) of IDH-wildtype GBM samples analyzed, including 41% (95/232) with a co-occurring EGFR amplification and mutation, 26% (61/232) with an EGFR domain truncation event, such as EGFRvIII, and 2.2% (5/232) with an EGFR fusion event[72]. No definitive correlation has been identified between EGFR amplification and length of survival in patients with GBM[73-74]; however, EGFR amplification has been associated with prolonged survival in patients over the age of 60 with GBM[75].

FINDING SUMMARY

EGFR encodes the epidermal growth factor receptor, which belongs to a class of proteins called receptor tyrosine kinases. In response to signals from the environment, EGFR passes biochemical messages to the cell that stimulate it to grow and divide[76]. The EGFR A289V mutation, located in the extracellular domain, has been shown to be activating[70]. Glioblastoma cell lines harboring an EGFR A289V or A289D mutation were shown to be dependent on EGFR kinase activity[71], and other mutations at this position are also likely activating. In addition, A289V is frequently associated with increased EGFR gene copy number[70].

GENE
PTEN

ALTERATION
P213fs*8 - subclonal

TRANSCRIPT ID
NM_000314.4

CODING SEQUENCE EFFECT
638delC

VARIANT CHROMOSOMAL POSITION
chr10:89717611-89717612

VARIANT ALLELE FREQUENCY (% VAF)
2.0%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

PTEN loss or mutation leads to activation of the PI3K-AKT-mTOR pathway and may predict sensitivity to inhibitors of this pathway[77-80]. Clinical studies in glioblastoma have not observed an association between PTEN deficiency and response to everolimus or temsirolimus[81-83]. Preclinical data indicate that PTEN loss or inactivation may predict sensitivity to PARP inhibitors[84-88], and clinical benefit has been observed for patients with PTEN-altered breast cancer including triple negative breast cancer[89], ovarian cancer[90], uterine leiomyosarcoma[91], and endometrial cancer[88] treated with PARP inhibitors. However, some studies have reported a lack of association between PTEN mutation and PARP inhibitor sensitivity[92-93].

FREQUENCY & PROGNOSIS

Studies in the literature have indicated that PTEN alterations (mutation or homozygous deletion) occur most frequently in glioblastoma (GBM), less frequently in anaplastic astrocytoma, and rarely in lower grade glioma subtypes including low grade astrocytoma, oligodendroglioma, oligoastrocytoma, and ependymoma[75,94-100]. One study detected PTEN mutation in 42% (97/232) and loss in 10% (24/232) of IDH-wildtype GBM samples analyzed[72]. In the TCGA dataset, PTEN mutation was observed in 23% of GBM cases and PTEN deletion was reported in 7% of cases[67], while in the Lower Grade Glioma TCGA dataset, PTEN mutation was observed in 4% of cases and homozygous deletion observed in 1.2% of cases[101]. Decreased PTEN expression is associated with the higher grade GBM tumors[102]. Loss of PTEN correlated with significantly worse prognosis in all grades of gliomas[97,103].

FINDING SUMMARY

PTEN encodes an inositol phosphatase that functions as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway; loss of PTEN can lead to uncontrolled cell growth and suppression of apoptosis[78]. Alterations such as seen here may disrupt PTEN function or expression[99,104-144].

POTENTIAL GERMLINE IMPLICATIONS

PTEN mutations underlie several inherited disorders, collectively termed PTEN hamartoma tumor syndrome (PHTS), which include Cowden syndrome (CS) and its variant Lhermitte-Duclos disease (LD), Bannayan-Riley-Ruvalcaba syndrome (BRRS), PTEN-related Proteus syndrome (PS), and Proteus-like syndrome[145-146]. The mutation rate for PTEN in these disorders ranges from 20 to 85% of patients[145,147]. The estimated incidence of Cowden syndrome is 1/200,000, which may be an underestimate due to the high variability of this disorder[145]. Given the association between PTEN and these inherited syndromes, in the appropriate clinical context, germline testing for mutations affecting PTEN is recommended.

GENE
CTNNB1

ALTERATION
splice site 1804-1G>A

TRANSCRIPT ID
NM_001904.3

CODING SEQUENCE EFFECT
1804-1G>A

VARIANT CHROMOSOMAL POSITION
chr3:41277839

VARIANT ALLELE FREQUENCY (% VAF)
18.3%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Mutation or activation of CTNNB1 signaling has been shown to increase mTOR signaling, promote tumorigenesis, and respond to mTOR inhibition in preclinical studies[148-150]. Small studies have reported clinical benefit following treatment of everolimus combined with other targeted agents for patients with CTNNB1-mutated hepatocellular carcinoma[151-152] or endometrial carcinoma[153]. In preclinical studies, CTNNB1 activating mutations have been shown to increase expression of WNT pathway member DKK1, which may promote tumor cell proliferation and immune evasion[154-156]. A Phase 1 trial of DKK1-targeting antibody DKN-01 in combination with paclitaxel in esophageal cancer reported a 50% (2/4) PR rate and 25% (1/4) SD rate in patients with CTNNB1 activating mutations, compared with 24% (10/41) PR and 37% (15/41) SD in unselected patients[157]. Multiple preclinical studies in cancer models harboring CTNNB1 mutation or beta-catenin pathway activation have reported activation of the NOTCH pathway and sensitivity to pharmacologic inhibition of NOTCH signaling by gamma-secretase inhibitors[158-161]. Clinical trials of gamma-secretase inhibitor nirogacestat have shown high response rates in patients with desmoid tumors, which are driven by activating CTNNB1 mutations in the majority of cases[162], suggesting CTNNB1-mutated tumors may be sensitive to gamma-secretase inhibitors. Although WNT pathway inhibitors have been explored preclinically in CTNNB1-mutated cells, clinical data supporting this therapeutic approach are lacking[149,163-165]. These approaches would not be relevant in the context of inactivating alterations, as seen here.

FREQUENCY & PROGNOSIS

CTNNB1 mutations are common in various solid tumors and are often seen in endometrial (14%), hepatobiliary (11%), melanoma (4.7%), prostate (3.4%), and non-small cell lung (2.9%) cancer (NSCLC)[166]. Overexpression of the components of the Wnt pathway, including beta-catenin, is common in glioblastoma, and Wnt/beta-catenin signaling has been implicated in the initiation, proliferation, and invasion of glioma[167-168]. This is frequently accomplished by hypermethylation or other inactivation of the negative regulators of the WNT/beta-catenin pathway, such as APC[169]. Increased beta-catenin expression has been correlated with poor prognosis in glioblastoma patients[170-171]. In preclinical studies, proliferation of glioma cell lines has been reported to be sensitive to WNT or beta-catenin inhibition[172].

FINDING SUMMARY

CTNNB1 encodes beta-catenin, a key downstream component of the WNT signaling pathway. Beta-catenin interacts with cadherin to regulate cell-cell adhesion; as a component of the WNT pathway, it also plays a role in development, cell proliferation, and cell differentiation[173]. Alterations such as seen here may disrupt CTNNB1 function or expression[174-175].

GENE
TERT

ALTERATION
promoter -124C>T

TRANSCRIPT ID
NM_198253.2

CODING SEQUENCE EFFECT
-124C>T

VARIANT CHROMOSOMAL POSITION
chr5:1295228

VARIANT ALLELE FREQUENCY (% VAF)
32.9%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Therapeutic options for targeting tumors with TERT mutations are limited, although a variety of approaches have been investigated, including immunotherapies using TERT as a tumor-associated antigen and antisense oligonucleotide- or peptide-based therapies. TERT peptide vaccines showed limited anticancer efficacy in clinical trials[176]; however, in one preclinical study, the combination of a TERT peptide vaccine and anti-CTLA-4 therapy suppressed tumor growth[177]. A Phase 2 study of the TERT inhibitor imetelstat for patients with advanced non-small cell lung cancer reported no improvement in PFS or OS[178].

FREQUENCY & PROGNOSIS

TERT promoter mutations have been reported in 51-59% of gliomas[179-180], most frequently in glioblastoma (GBM, 54-84%), gliosarcoma (81%), oligodendroglioma (78%), and historically in oligoastrocytomas (25-31%) but less frequently in lower grade astrocytomas (10-18%) and in only 1% of ependymomas[179-183]. In patients with glioblastoma (GBM), the prevalence of TERT promoter mutation is lower in pediatric primary GBM (11%) and adult secondary GBM (28%) compared with adult primary GBM (58-83%)[179,181]. One study detected TERT promoter mutations in 78% (181/232) of IDH-wildtype GBM samples analyzed[72]. TERT promoter mutation has been shown to be significantly associated with increased TERT gene expression in astrocytoma, oligodendroglioma, and GBM[184]. TERT promoter mutations significantly associate with poor prognosis in patients with GBM, although this correlation may be due to the association with primary GBM as opposed to IDH-positive secondary GBM[179,181,184-185]. In the context of IDH-wildtype glioma, TERT mutations are associated with reduced OS (NCCN CNS Cancers Guidelines, v1.2022).

FINDING SUMMARY

Telomerase reverse transcriptase (TERT, or hTERT) is a catalytic subunit of the telomerase complex, which is required to maintain appropriate chromosomal length[186]. Activation of TERT is a hallmark of cancer, being detected in up to 80-90% of malignancies and absent in quiescent cells[187-189]. Mutations within the promoter region of TERT that confer enhanced TERT promoter activity have been reported in two hotspots, located at -124 bp and -146 bp upstream of the transcriptional start site (also termed C228T and C250T, respectively)[190-192], as well as tandem mutations at positions –124/–125 bp and –138/–139 bp[190].

POTENTIAL DIAGNOSTIC IMPLICATIONS

TERT mutations are associated with 1p/19q co-deletion in oligodendrogliomas, and are highly recurrent in IDH/ATRX-wildtype glioblastoma (GBM) (NCCN CNS Cancers Guidelines, v1.2022)[193]. The presence of EGFR gene amplification or TERT promoter mutations are indicative of diffuse astrocytic glioma with molecular features of glioblastoma, WHO grade 4 in IDH1/2-wildtype tumors (NCCN CNS Cancers Guidelines, v1.2022)[194].

GENE
TP53

ALTERATION
K132E

TRANSCRIPT ID
NM_000546.4

CODING SEQUENCE EFFECT
394A>G

VARIANT CHROMOSOMAL POSITION
chr17:7578536

VARIANT ALLELE FREQUENCY (% VAF)
60.0%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[195-198] or p53 gene therapy such as SGT53[199-203]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[204]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[205]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[206]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[207]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[208]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[209]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[210]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[203]. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[211]. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)[212].

FREQUENCY & PROGNOSIS

In the TCGA dataset, TP53 alterations have been reported in 35% of glioblastomas (GBMs), with a high incidence in pediatric and secondary GBMs and a low incidence in primary GBMs[213-214]. One study detected TP53 alterations in 31% (73/232) of IDH-wildtype GBM samples analyzed, with most of the events being mutations[72]. TP53 mutations have been reported in 18-40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively[215-220]. Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM)[221]. One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH-wildtype GBM[72]. Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN[222].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[223]. Alterations such as seen here may disrupt TP53 function or expression[224-228].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2022)[229]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[230-232], including sarcomas[233-234]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[235] to 1:20,000[234]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[236]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[237-242]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[237-238]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[243]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[241,244-245]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Erlotinib

Assay findings association

EGFR
A289T

AREAS OF THERAPEUTIC USE

Erlotinib is a small-molecule inhibitor of EGFR. It is FDA approved as a monotherapy or in combination with ramucirumab for patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 (L858R) mutations. Erlotinib is also FDA approved in combination with gemcitabine as a first-line treatment for advanced pancreatic cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Amplification or activation of EGFR may predict sensitivity to therapies such as erlotinib. For patients with activating mutations in EGFR, treatment with erlotinib has been associated with improved response and lengthened time to progression[47,246-248] .

SUPPORTING DATA

In the MyPathway Phase 2a basket study for advanced solid tumors, 1 of 9 patients with EGFR activation mutations responded to erlotinib monotherapy; the responding patient had urethral adenocarcinoma[249]. A patient with EGFR-mutated metastatic lacrimal gland adenoid cystic carcinoma experienced clinical benefit from erlotinib treatment that was ongoing at 14 months[250]. A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response[251]. In a Phase 2 study of 65 patients with GBM or gliosarcoma, treatment with erlotinib, temozolomide, and radiotherapy resulted in longer progression-free survival relative to a historical control study utilizing a regimen of temozolomide and radiotherapy alone (19.3 months vs. 14.1 months)[252]. However, in a Phase 1/2 trial of erlotinib monotherapy in 11 patients with relapsed or refractory GBM or anaplastic astrocytoma, all patients showed disease progression and the drug showed significant toxicity[253]. In addition, a Phase 2 trial of patients with recurrent or progressive GBM treated with erlotinib and sorafenib did not meet its objective of a 30% increase in overall survival time compared with historical controls; sorafenib was found to increase erlotinib clearance[254].

Gefitinib

Assay findings association

EGFR
A289T

AREAS OF THERAPEUTIC USE

Gefitinib targets the tyrosine kinase EGFR and is FDA approved to treat non-small cell lung cancer (NSCLC) harboring exon 19 deletions or exon 21 (L858R) substitution mutations in EGFR. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Activation of EGFR may predict sensitivity to therapies such as gefitinib. Clinical studies have consistently shown significant improvement in response rates and PFS for patients with EGFR-mutated non-small cell lung cancer (NSCLC) treated with gefitinib compared with chemotherapy[248,255-260] , and responses have been reported for patients with EGFR-rearranged NSCLC[261-262] .

SUPPORTING DATA

A clinical study of patients with glioblastoma (GBM) treated with gefitinib or erlotinib found that 9/49 (18%) had tumor shrinkage of 25% or more; in this study, the extracellular domain EGFRvIII mutation was correlated with response[251]. A Phase 2 clinical study of gefitinib in patients with high-grade glioma (including GBM, anaplastic astrocytoma, and oligodendroglioma) reported 18% (5/28) disease stabilization; efficacy was not correlated with EGFR expression[263]. However, a Phase 1/2 clinical trial of gefitinib combined with radiotherapy in 178 patients with GBM reported no overall survival benefit of added gefitinib, and EGFR expression was found to be of no prognostic value for patients treated with gefitinib plus radiotherapy[264]. A Phase 2 trial of preoperative gefitinib treatment in patients with recurrent GBM reported that although EGFR phosphorylation was decreased in treated patients as compared to the control group, measurement of 12 downstream molecules revealed no significant changes[265].

Osimertinib

Assay findings association

EGFR
A289T

AREAS OF THERAPEUTIC USE

Osimertinib is an irreversible EGFR TKI that is selective for EGFR TKI-sensitizing mutations and the EGFR T790M mutation. It is FDA approved in various treatment settings for patients with non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions, exon 21 L858R mutations, or T790M mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

EGFR TKI-sensitizing mutations or rearrangements and/or the EGFR T790M mutation may predict sensitivity to osimertinib in non-small cell lung cancer[57,261,266-268] . EGFR mutations may confer sensitivity to osimertinib on the basis of clinical responses to the third-generation TKI osimertinib for patients with EGFR-mutated glioma[64-65] and additional clinical studies suggesting clinical benefit for these patients[61,269] .

SUPPORTING DATA

Clinical benefit from osimertinib has been observed for cases of pediatric and adult patients with EGFR-altered glioma[61,64-65,269-270] . Osimertinib has been studied primarily for the treatment of EGFR-mutated NSCLC. The Phase 3 FLAURA study reported that, relative to erlotinib or gefitinib, first-line osimertinib significantly increased both median PFS (mPFS; 18.9 vs. 10.2 months, HR=0.46) and median OS (38.6 vs. 31.8 months; HR=0.80) for patients with advanced non-small cell lung cancer (NSCLC) and activating, sensitizing EGFR mutations (specifically, exon 19 deletion or L858)[266,271] . In the Phase 3 ADAURA study, patients with early-stage (IB/II/IIIA) EGFR-mutated NSCLC experienced longer disease-free survival on osimertinib compared with placebo in the adjuvant setting (65.8 vs. 28.1 months, HR=0.27)[272]. A Phase 1 study reported that T790M-negative patients with acquired EGFR TKI resistance experienced an ORR of 21% and a median PFS of 2.8 months[57]. A Phase 1b/2 study evaluating osimertinib in combination with the CD73 inhibitor oleclumab for patients with advanced EGFR-mutated, T790M-negative NSCLC reported an ORR of 19% (4/21), a DCR of 81%, and mPFS of 11 months (Kim et al., 2021 AACR Abstract CT163). A Phase 2 study of osimertinib for EGFR-TKI-naive patients with metastatic or recurrent NSCLC and uncommon EGFR mutations reported a 50% (18/36) ORR and an 89% (32/36) DCR with a median PFS of 8.2 months and a median duration of response of 11.2 months; patients harboring L861Q, G719X, or S768I mutations had ORRs of 78% (7/9), 53% (10/19), and 38% (3/8), respectively[273]. A Phase 2 trial of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with untreated advanced non-small cell lung cancer (NSCLC) harboring EGFR del19 or L858R reported no difference in ORR (82% vs 86%) and median PFS (22.1 vs 20.2 months, HR 0.862 p=0.213)[274]. The Phase 2 BOOSTER study of osimertinib in combination with bevacizumab versus osimertinib monotherapy for patients with advanced NSCLC with EGFR-sensitizing mutations (exon 19 del or L858R) and L790M at progression on prior EGFR TKI reported no difference in ORR (55% vs 55%), median OS (24.0 vs 24.3 months, HR 1.03 p=0.91), or median PFS (15.4 vs 12.3 months, HR 0.96 p=0.83), although improved PFS was observed for the combination in the subgroup of current or former smokers (16.5 vs 8.4, HR 0.52) while nonsmokers had no benefit (HR 1.47)[275]. The Phase 1b TATTON study of osimertinib in combination with selumetinib, savolitinib, or durvalumab for patients with previously treated EGFR-mutated NSCLC reported ORRs of 42% (15/36), 44% (8/18), and 44% (10/23), respectively[276].

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
EGFR

ALTERATION
A289T

RATIONALE
EGFR activating mutations, rearrangements, or amplification may predict sensitivity to EGFR-targeted therapies. Strategies to overcome resistance to current agents include next-generation EGFR inhibitors and combination therapies.

NCT03239015

PHASE 2

Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event

TARGETS
EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT03783403

PHASE 1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

TARGETS
CD20, EGFR, SIRP-alpha

LOCATIONS: Seoul (Korea, Republic of), Heidelberg (Australia), Melbourne (Australia), Manchester (United Kingdom), Edmonton (Canada), Rouen (France), Oregon, Marseille (France), Creteil (France), Nantes Cedex 01 (France)

NCT04946968

PHASE 2

Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 lncRNA Expr or Other Novel Emerging Biomarkers

TARGETS
ERBB4, EGFR, ERBB2

LOCATIONS: Singapore (Singapore)

NCT04670679

PHASE 1

A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors

TARGETS
SHP2, EGFR

LOCATIONS: Perth (Australia), Melbourne (Australia), Nevada, California, Missouri, Texas, Massachusetts, New York, Tennessee

NCT04616196

PHASE 1/2

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

TARGETS
EGFR

LOCATIONS: California, Montana, Arizona, Minnesota, Illinois, Michigan, Texas, New York

NCT04720976

PHASE 1/2

JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

TARGETS
MEK, SHP2, PD-1, EGFR, KRAS

LOCATIONS: Utah, California, Arizona, Minnesota, Illinois, Michigan, Oklahoma, Missouri, Indiana, Connecticut

NCT02800486

PHASE 2

Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA

TARGETS
EGFR

LOCATIONS: New York

NCT02861898

PHASE 1/2

Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma

TARGETS
EGFR

LOCATIONS: New York

GENE
PTEN

ALTERATION
P213fs*8 - subclonal

RATIONALE
PTEN loss or inactivating mutations may lead to increased activation of the PI3K-AKT-mTOR pathway and may indicate sensitivity to inhibitors of this pathway. PTEN loss or inactivation may also predict sensitivity to PARP inhibitors.

NCT04337463

PHASE NULL

ATG-008 Combined With Toripalimab in Advanced Solid Tumors

TARGETS
mTORC1, mTORC2, PD-1

LOCATIONS: Chongqing (China), Chengdu (China)

NCT04740190

PHASE 2

Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd

TARGETS
PARP

LOCATIONS: Hong Kong (Hong Kong)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT05035745

PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561

PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

NCT04614909

PHASE NULL

Phase 0/2 Study of Pamiparib in Newly Diagnosed and rGBM

TARGETS
PARP

LOCATIONS: Arizona

NCT05076513

PHASE NULL

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

TARGETS
PARP

LOCATIONS: Arizona

NCT04801966

PHASE NULL

Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study

TARGETS
CDK4, CDK6, PI3K-alpha, PD-L1, MEK, PARP, PD-1, BRAF

LOCATIONS: Melbourne (Australia)

NCT04497116

PHASE 1/2

Study of RP-3500 in Advanced Solid Tumors

TARGETS
ATR, PARP

LOCATIONS: Copenhagen (Denmark), Newcastle Upon Tyne (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Illinois, Toronto (Canada), Massachusetts, Rhode Island, New York, Tennessee

NCT04991480

PHASE 1/2

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

TARGETS
PARP, Pol theta

LOCATIONS: London (United Kingdom), Oklahoma, Connecticut, New York, Pennsylvania, Tennessee, Texas, Florida

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ABL1
R483Q

AXIN1
R412W

BCOR
K1137R

CDKN2A/B
P3S

DIS3
M536V

ESR1
G145S

FLCN
A290V

KDM5A
G284D

KMT2A (MLL)
S215P

PIK3C2G
I459N

ROS1
A474T

TSC2
R786H

WHSC1 (MMSET)
rearrangement

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	*ACVR1B*	*AKT1*	*AKT2*	*AKT3*	*ALK*	*ALOX12B*	*AMER1 (FAM123B or WTX)*	
APC	*AR*	*ARAF*	*ARFRP1*	*ARID1A*	*ASXL1*	*ATM*	*ATR*	*ATRX*
AURKA	*AURKB*	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*
BCL6	*BCOR*	*BCORL1*	*BRAF*	*BRCA1*	*BRCA2*	*BRD4*	*BRIP1*	*BTG1*
BTG2	*BTK*	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*	*CCND1*	*CCND2*
CCND3	*CCNE1*	*CD22*	*CD274 (PD-L1)*	*CD70*	*CD79A*	*CD79B*	*CDC73*	*CDH1*
CDK12	*CDK4*	*CDK6*	*CDK8*	*CDKN1A*	*CDKN1B*	*CDKN2A*	*CDKN2B*	*CDKN2C*
CEBPA	*CHEK1*	*CHEK2*	*CIC*	*CREBBP*	*CRKL*	*CSF1R*	*CSF3R*	*CTCF*
CTNNA1	*CTNNB1*	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*	*DAXX*	*DDR1*	*DDR2*
DIS3	*DNMT3A*	*DOT1L*	*EED*	*EGFR*	*EMSY (C11orf30)*	*EP300*	*EPHA3*	*EPHB1*
EPHB4	*ERBB2*	*ERBB3*	*ERBB4*	*ERCC4*	*ERG*	*ERRFI1*	*ESR1*	*EZH2*
FANCA	*FANCC*	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*
FGF19	*FGF23*	*FGF3*	*FGF4*	*FGF6*	*FGFR1*	*FGFR2*	*FGFR3*	*FGFR4*
FH	*FLCN*	*FLT1*	*FLT3*	*FOXL2*	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*
GATA6	*GID4 (C17orf39)*	*GNA11*	*GNA13*	*GNAQ*	*GNAS*	*GRM3*	*GSK3B*	*H3-3A (H3F3A)*
HDAC1	*HGF*	*HNF1A*	*HRAS*	*HSD3B1*	*ID3*	*IDH1*	*IDH2*	*IGF1R*
IKBKE	*IKZF1*	*INPP4B*	*IRF2*	*IRF4*	*IRS2*	*JAK1*	*JAK2*	*JAK3*
JUN	*KDM5A*	*KDM5C*	*KDM6A*	*KDR*	*KEAP1*	*KEL*	*KIT*	*KLHL6*
KMT2A (MLL)	*KMT2D (MLL2)*	*KRAS*	*LTK*	*LYN*	*MAF*	*MAP2K1 (MEK1)*	*MAP2K2 (MEK2)*	*MAP2K4*
MAP3K1	*MAP3K13*	*MAPK1*	*MCL1*	*MDM2*	*MDM4*	*MED12*	*MEF2B*	*MEN1*
MERTK	*MET*	*MITF*	*MKNK1*	*MLH1*	*MPL*	*MRE11 (MRE11A)*	*MSH2*	*MSH3*
MSH6	*MST1R*	*MTAP*	*MTOR*	*MUTYH*	*MYC*	*MYCL (MYCL1)*	*MYCN*	*MYD88*
NBN	*NF1*	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2*	*NOTCH3*
NPM1	*NRAS*	*NSD2 (WHSC1 or MMSET)*		*NSD3 (WHSC1L1)*	*NT5C2*	*NTRK1*	*NTRK2*	*NTRK3*
P2RY8	*PALB2*	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1 (PD-1)*	*PDCD1LG2 (PD-L2)*
PDGFRA	*PDGFRB*	*PDK1*	*PIK3C2B*	*PIK3C2G*	*PIK3CA*	*PIK3CB*	*PIK3R1*	*PIM1*
PMS2	*POLD1*	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*
PRKN (PARK2)	*PTCH1*	*PTEN*	*PTPN11*	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*
RAD51B	*RAD51C*	*RAD51D*	*RAD52*	*RAD54L*	*RAF1*	*RARA*	*RB1*	*RBM10*
REL	*RET*	*RICTOR*	*RNF43*	*ROS1*	*RPTOR*	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*	*SMO*
SNCAIP	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*	*STAT3*
STK11	*SUFU*	*SYK*	*TBX3*	*TEK*	*TENT5C (FAM46C)*		*TET2*	*TGFBR2*
TIPARP	*TNFAIP3*	*TNFRSF14*	*TP53*	*TSC1*	*TSC2*	*TYRO3*	*U2AF1*	*VEGFA*
VHL	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	*BCL2*	*BCR*	*BRAF*	*BRCA1*	*BRCA2*	*CD74*	*EGFR*	*ETV4*
ETV5	*ETV6*	*EWSR1*	*EZR*	*FGFR1*	*FGFR2*	*FGFR3*	*KIT*	*KMT2A (MLL)*
MSH2	*MYB*	*MYC*	*NOTCH2*	*NTRK1*	*NTRK2*	*NUTM1*	*PDGFRA*	*RAF1*
RARA	*RET*	*ROS1*	*RSPO2*	*SDC4*	*SLC34A2*	*TERC**	*TERT***	*TMPRSS2*

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status
Loss of Heterozygosity (LOH) score
Microsatellite (MS) status
Tumor Mutational Burden (TMB)

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.
3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.
4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.
5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.
6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.
7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

**Interquartile Range = 1st Quartile to 3rd Quartile*

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2*, and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.6.0

The median exon coverage for this sample is 962x

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Martinez R, et al. Oncology (2004) pmid: 15331927
7. Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285
8. Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554
9. Szybka M, et al. Clin. Neuropathol. () pmid: 12908754
10. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
11. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
12. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
13. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
14. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
15. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
16. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
17. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
18. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
19. Cristescu R, et al. Science (2018) pmid: 30309915
20. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
21. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
22. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
24. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
25. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
26. Zhao J, et al. Nat. Med. (2019) pmid: 30742119
27. Touat M, et al. Nature (2020) pmid: 32322066
28. Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570
29. Johanns TM, et al. Cancer Discov (2016) pmid: 27683556
30. Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642
31. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
32. Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112
33. Johnson A, et al. Oncologist (2017) pmid: 28912153
34. Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864
35. Wang L, et al. BMC Cancer (2020) pmid: 32164609
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Rosell R, et al. Lancet Oncol. (2012) pmid: 22285168
48. Douillard JY, et al. Br. J. Cancer (2014) pmid: 24263064
49. Hayashi T, et al. Hum Pathol (2020) pmid: 32673682
50. Cao L, et al. Onco Targets Ther (2018) pmid: 29780256
51. Yang TY, et al. J. Clin. Oncol. (2011) pmid: 21422421
52. Sequist LV, et al. J. Clin. Oncol. (2013) pmid: 23816960
53. Qin BD, et al. Onco Targets Ther (2018) pmid: 30127622
54. Frega S, et al. J Thorac Oncol (2016) pmid: 27131295
55. Long X, et al. Onco Targets Ther (2020) pmid: 33116645
56. Mok TS, et al. J. Clin. Oncol. (2018) pmid: 29864379
57. Jänne PA, et al. N. Engl. J. Med. (2015) pmid: 25923549
58. Hong MH, et al. Cancer (2020) pmid: 32749686
59. Kim HS, et al. Oncotarget (2015) pmid: 26462025
60. Kim HS, et al. Clin. Cancer Res. (2015) pmid: 25424851
61. Mondal G, et al. Acta Neuropathol (2020) pmid: 32303840
62. Cavalieri S, et al. Eur. J. Cancer (2018) pmid: 29734047
63. Chi AS, et al. JCO Precis Oncol (2020) pmid: 32923886
64. Makhlin I, et al. CNS Oncol (2019) pmid: 31769726
65. Goyal A, et al. World Neurosurg (2021) pmid: 33940677
66. Jonsson P, et al. Clin. Cancer Res. (2019) pmid: 31263031
67. Brennan CW, et al. Cell (2013) pmid: 24120142
68. Ceccarelli M, et al. Cell (2016) pmid: 26824661
69. Thomas AA, et al. Neuro-oncology (2017) pmid: 28472509
70. Lee JC, et al. PLoS Med. (2006) pmid: 17177598
71. Vivanco I, et al. Cancer Discov (2012) pmid: 22588883
72. Yan et al. 2020; DOI:10.1200/PO.19.00385
73. Srividya MR, et al. J. Clin. Pathol. (2010) pmid: 20702468
74. Das P, et al. J Clin Neurosci (2011) pmid: 20888234
75. Smith JS, et al. J. Natl. Cancer Inst. (2001) pmid: 11504770
76. Ciardiello F, et al. N. Engl. J. Med. (2008) pmid: 18337605
77. Courtney KD, et al. J. Clin. Oncol. (2010) pmid: 20085938
78. Simpson L, et al. Exp. Cell Res. (2001) pmid: 11237521
79. Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108
80. Milella M, et al. Sci Rep (2017) pmid: 28220839
81. Galanis E, et al. J. Clin. Oncol. (2005) pmid: 15998902
82. Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475
83. Mason WP, et al. Invest New Drugs (2012) pmid: 22160854
84. Mendes-Pereira AM, et al. EMBO Mol Med (2009) pmid: 20049735
85. Shen Y, et al. Clin. Cancer Res. (2013) pmid: 23881923
86. Chatterjee P, et al. PLoS ONE (2013) pmid: 23565244
87. McCormick A, et al. Int. J. Gynecol. Cancer (2016) pmid: 26905328
88. Forster MD, et al. Nat Rev Clin Oncol (2011) pmid: 21468130
89. Eikesdal HP, et al. Ann Oncol (2021) pmid: 33242536
90. Dougherty et al., 2014; ASCO Abstract 5536
91. Pan M, et al. Perm J (2021) pmid: 33970096
92. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
93. Romero I, et al. Gynecol Oncol (2020) pmid: 32988624
94. Zhou XP, et al. Int. J. Cancer (1999) pmid: 10096247
95. Rasheed BK, et al. Cancer Res. (1997) pmid: 9331072
96. Davies MP, et al. Br. J. Cancer (1999) pmid: 10188904
97. Lin H, et al. Clin. Cancer Res. (1998) pmid: 9796977
98. Schmidt EE, et al. J. Neuropathol. Exp. Neurol. (1999) pmid: 10560660
99. Kato H, et al. Clin. Cancer Res. (2000) pmid: 11051241
100. Furnari FB, et al. Genes Dev. (2007) pmid: 17974913
101. Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751
102. Sano T, et al. Cancer Res. (1999) pmid: 10213484
103. Srividya MR, et al. Neuropathology (2011) pmid: 21134002
104. Campbell RB, et al. J. Biol. Chem. (2003) pmid: 12857747
105. Rodríguez-Escudero I, et al. Hum. Mol. Genet. (2011) pmid: 21828076
106. He X, et al. Cancer Res. (2013) pmid: 23475934
107. Han SY, et al. Cancer Res. (2000) pmid: 10866302
108. Myers MP, et al. Proc. Natl. Acad. Sci. U.S.A. (1998) pmid: 9811831
109. Pradella LM, et al. BMC Cancer (2014) pmid: 24498881
110. Kim JS, et al. Mol. Cell. Biol. (2011) pmid: 21536651
111. Denning G, et al. Oncogene (2007) pmid: 17213812
112. Hlobilkova A, et al. Anticancer Res. () pmid: 16619501
113. Redfern RE, et al. Protein Sci. (2010) pmid: 20718038
114. Shenoy S, et al. PLoS ONE (2012) pmid: 22505997
115. Wang Y, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19329485
116. Okumura K, et al. J. Biol. Chem. (2006) pmid: 16829519
117. Lee JO, et al. Cell (1999) pmid: 10555148
118. Maxwell GL, et al. Cancer Res. (1998) pmid: 9635567
119. Risinger JI, et al. Clin. Cancer Res. (1998) pmid: 9865913
120. Fenton TR, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22891331
121. Ngeow J, et al. J. Clin. Endocrinol. Metab. (2012) pmid: 23066114
122. Lobo GP, et al. Hum. Mol. Genet. (2009) pmid: 19457929
123. Liu J, et al. Oncogene (2014) pmid: 23995781
124. Maehama T, et al. Annu. Rev. Biochem. (2001) pmid: 11395408
125. De Vivo I, et al. J. Med. Genet. (2000) pmid: 10807691
126. Ramaswamy S, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10051603
127. Liu JL, et al. Mol. Cell. Biol. (2005) pmid: 15988030
128. Karoui M, et al. Br. J. Cancer (2004) pmid: 15026806
129. Gil A, et al. PLoS ONE (2015) pmid: 25875300
130. Furnari FB, et al. Cancer Res. (1998) pmid: 9823298
131. Spinelli L, et al. J. Med. Genet. (2015) pmid: 25527629
132. Mingo J, et al. Eur. J. Hum. Genet. (2018) pmid: 29706633
133. Wang Q, et al. J. Mol. Graph. Model. (2010) pmid: 20538496
134. Andrés-Pons A, et al. Cancer Res. (2007) pmid: 17942903
135. Butler MG, et al. J. Med. Genet. (2005) pmid: 15805158
136. Georgescu MM, et al. Proc. Natl. Acad. Sci. U.S.A. (1999) pmid: 10468583
137. Staal FJ, et al. Br. J. Cancer (2002) pmid: 12085208
138. Nguyen HN, et al. Oncogene (2014) pmid: 24292679
139. Rahdar M, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19114656
140. Das S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12808147
141. Wang X, et al. Biochem. J. (2008) pmid: 18498243
142. Valiente M, et al. J. Biol. Chem. (2005) pmid: 15951562
143. Nguyen HN, et al. Oncogene (2015) pmid: 25263454
144. Shan L, et al. Cell Discov (2020) pmid: 32704382
145. Blumenthal GM, et al. Eur. J. Hum. Genet. (2008) pmid: 18781191
146. Orloff MS, et al. Oncogene (2008) pmid: 18794875
147. Zbuk KM, et al. Nat. Rev. Cancer (2007) pmid: 17167516
148. Tanwar PS, et al. Biol. Reprod. (2009) pmid: 19403928
149. Tanwar PS, et al. PLoS ONE (2011) pmid: 21695255
150. Fujishita T, et al. Proc. Natl. Acad. Sci. U.S.A. (2008) pmid: 18768809
151. Bhoori S, et al. J. Hepatol. (2010) pmid: 20347502

152. Janku F, et al. Oncotarget (2014) pmid: 24931142
153. Slomovitz BM, et al. J. Clin. Oncol. (2015) pmid: 25624430
154. Niida A, et al. Oncogene (2004) pmid: 15378020
155. Chamorro MN, et al. EMBO J. (2005) pmid: 15592430
156. Kagey MH, et al. Br. J. Pharmacol. (2017) pmid: 28574171
157. Kagey et al., 2017; AACR Abstract 369
158. Kwon C, et al. Nat. Cell Biol. (2011) pmid: 21841793
159. Arcaroli JJ, et al. Br. J. Cancer (2013) pmid: 23868008
160. Shang H, et al. Cancer (2015) pmid: 26349011
161. Kode A, et al. Nature (2014) pmid: 24429522
162. Messersmith WA, et al. Clin. Cancer Res. (2015) pmid: 25231399
163. Zhu J, et al. Carcinogenesis (2012) pmid: 22964660
164. Kogan Y, et al. Biochem. J. (2012) pmid: 22356261
165. Lachenmayer A, et al. Clin. Cancer Res. (2012) pmid: 22811581
166. Zehir A, et al. Nat. Med. (2017) pmid: 28481359
167. Nager M, et al. Chemother Res Pract (2012) pmid: 22400111
168. De Robertis A, et al. Mol. Cancer Ther. (2013) pmid: 23619303
169. Paul I, et al. Genes Cancer (2013) pmid: 24386505
170. Rossi M, et al. Cancer Biol. Ther. (2011) pmid: 21321483
171. Liu X, et al. Med. Oncol. (2011) pmid: 20300972
172. Pu P, et al. Cancer Gene Ther. (2009) pmid: 18949017
173. Biochem. Biophys. Res. Commun. (2000) pmid: 10679188
174. Hsu SC, et al. Mol. Cell. Biol. (1998) pmid: 9671490
175. Cong F, et al. Mol. Cell. Biol. (2003) pmid: 14612392
176. Nat Rev Clin Oncol (2017) pmid: 27245281
177. Duperret EK, et al. Mol Ther (2018) pmid: 29249395
178. Chiappori AA, et al. Ann Oncol (2015) pmid: 25467017
179. Killela PJ, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23530248
180. Killela PJ, et al. Oncotarget (2014) pmid: 24722048
181. Nonoguchi N, et al. Acta Neuropathol. (2013) pmid: 23955565
182. Liu X, et al. Cell Cycle (2013) pmid: 23603989
183. Koelsche C, et al. Acta Neuropathol. (2013) pmid: 24154961
184. Arita H, et al. Acta Neuropathol. (2013) pmid: 23764841
185. Reitman ZJ, et al. Acta Neuropathol. (2013) pmid: 24217890
186. Shay JW, et al. Semin. Cancer Biol. (2011) pmid: 22015685
187. Shay JW, et al. Eur. J. Cancer (1997) pmid: 9282118
188. Kim NW, et al. Science (1994) pmid: 7605428
189. Hanahan D, et al. Cell (2000) pmid: 10647931
190. Horn S, et al. Science (2013) pmid: 23348503
191. Huang FW, et al. Science (2013) pmid: 23348506
192. Vinagre J, et al. Nat Commun (2013) pmid: 23887589
193. Weller M, et al. Nat Rev Clin Oncol (2021) pmid: 33293629
194. Louis DN, et al. Neuro Oncol (2021) pmid: 34185076
195. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
196. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
197. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
198. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
199. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
200. Xu L, et al. Mol. Med. (2001) pmid: 11713371
201. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
202. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
203. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
204. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
205. Moore et al., 2019; ASCO Abstract 5513
206. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
207. Oza et al., 2015; ASCO Abstract 5506
208. Lee J, et al. Cancer Discov (2019) pmid: 31315834
209. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
210. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
211. Gourley et al., 2016; ASCO Abstract 5571
212. Park H, et al. ESMO Open (2022) pmid: 36084396
213. Nature (2008) pmid: 18772890
214. Jha P, et al. Diagn. Mol. Pathol. (2011) pmid: 22089350
215. Uno M, et al. Cancer Lett. (2005) pmid: 15914282
216. Uno M, et al. Int. J. Biol. Markers () pmid: 16711514
217. Lass U, et al. PLoS ONE (2012) pmid: 22844452
218. Faria MH, et al. APMIS (2012) pmid: 23009112
219. Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143
220. Galatro TF, et al. PLoS ONE (2013) pmid: 23613880
221. Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587
222. Nozaki M, et al. Neuro-oncology (1999) pmid: 11550308
223. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
224. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
225. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
226. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
227. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
228. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
229. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
230. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
231. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
232. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
233. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
234. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
235. Lalloo F, et al. Lancet (2003) pmid: 12672316
236. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
237. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
238. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
239. Xie M, et al. Nat. Med. (2014) pmid: 25326804
240. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
241. Severson EA, et al. Blood (2018) pmid: 29678827
242. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
243. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
244. Chabon JJ, et al. Nature (2020) pmid: 32269342
245. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
246. Cappuzzo F, et al. Lancet Oncol. (2010) pmid: 20493771
247. Zhong WZ, et al. J. Clin. Oncol. (2019) pmid: 31194613
248. Petrelli F, et al. Clin Lung Cancer (2012) pmid: 22056888
249. Hainsworth JD, et al. J. Clin. Oncol. (2018) pmid: 29320312
250. Nie KK, et al. Chin Med J (Engl) (2018) pmid: 29998897
251. Mellinghoff IK, et al. N. Engl. J. Med. (2005) pmid: 16282176
252. Prados MD, et al. J. Clin. Oncol. (2009) pmid: 19075262
253. Kesavabhotla K, et al. J. Exp. Ther. Oncol. (2012) pmid: 22946346
254. Peereboom DM, et al. Neuro-oncology (2013) pmid: 23328813
255. Han JY, et al. J. Clin. Oncol. (2012) pmid: 22370314
256. Maemondo M, et al. N. Engl. J. Med. (2010) pmid: 20573926
257. Mitsudomi T, et al. Lancet Oncol. (2010) pmid: 20022809
258. Mok TS, et al. N. Engl. J. Med. (2009) pmid: 19692680
259. Qi WX, et al. Curr Med Res Opin (2015) pmid: 25329826
260. Zhao H, et al. J Thorac Oncol (2015) pmid: 25546556
261. Wang J, et al. Int. J. Cancer (2019) pmid: 30255937
262. Baik CS, et al. J Thorac Oncol (2015) pmid: 26398831
263. Franceschi E, et al. Br. J. Cancer (2007) pmid: 17353924
264. Chakravarti A, et al. Int. J. Radiat. Oncol. Biol. Phys. (2013) pmid: 23182702
265. Hegi ME, et al. Mol. Cancer Ther. (2011) pmid: 21471286
266. Soria JC, et al. N. Engl. J. Med. (2018) pmid: 29151359
267. Alanazi A, et al. Lung Cancer Manag (2020) pmid: 33318755
268. Kim et al., 2021; DOI: 10.1200/PO.20.00296
269. Abousand et al., 2021; DOI: 10.26502/jcsct.5079114
270. Cardona AF, et al. J Neurooncol (2021) pmid: 34498213
271. Ramalingam SS, et al. N. Engl. J. Med. (2019) pmid: 31751012
272. Tsuboi et al., 2022; ESMO Abstract LBA47
273. Cho JH, et al. J. Clin. Oncol. (2019) pmid: 31825714
274. Kenmotsu H, et al. J Thorac Oncol (2022) pmid: 35636696
275. Soo et al., 2021; ESMO Abstract VP3-2021
276. Oxnard GR, et al. Ann. Oncol. (2020) pmid: 32139298